dolasetron mesylate

Known as: 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1), dolasetron mesylate monohydrate, dolasetron mesilate monohydrate 
An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of… (More)

Topic mentions per year

Topic mentions per year

1993-2016
051019932016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
PURPOSE The incidence of postoperative nausea and vomiting (PONV) varies from 50% to 75% after gynaecological surgery under… (More)
Is this relevant?
1997
1997
UNLABELLED This study was conducted to determine the efficacy and safety of four intravenous (I.V.) doses of dolasetron, an… (More)
Is this relevant?
1997
1997
PURPOSE This double-blind, dose-response study was conducted to assess the safety and efficacy of four oral doses of dolasetron… (More)
Is this relevant?
1997
1997
PURPOSE To compare the efficacy of dolasetron and ondansetron in controlling nausea and vomiting in the first 24 hours; to… (More)
Is this relevant?
1997
1997
Twenty-four healthy women received 2.4 mg kg-1 dolasetron mesylate (1.8 mg kg-1 dolasetron base) by a 10 min intravenous… (More)
Is this relevant?
1996
1996
A single-blind, randomized, five-way cross-over, safety and tolerability trial was conducted to determine whether intravenous (i… (More)
Is this relevant?
1996
1996
PURPOSE To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in… (More)
Is this relevant?
1995
1995
Dolasetron mesylate is a selective and potent 5-HT3 receptor antagonist. This drug is currently in development for the treatment… (More)
Is this relevant?
1994
1994
PURPOSE This dose-ranging trial of intravenous dolasetron mesylate (MDL73,147EF) was performed to determine its adverse and… (More)
Is this relevant?
1994
1994
Dolasetron mesylate (MDL 73,147EF), a new serotonin receptor (5-HT3) antagonist was administered to 164 cancer patients naive or… (More)
Is this relevant?